U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06810167) titled 'Assessing Tenapanor As a Treatment of CF-related Constipation.' on Jan. 23.
Brief Summary: Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Cyst...